News and Updates for Healthcare Professionals

The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome)…

In 2020, 54 million US adults with chronic pain managed their symptoms with a mix of medication and nonpharmacologic therapies but one in four relied on medication alone, data from the Centers for Disease Control and Prevention (CDC) show.

HAMBURG, Germany – Use of some antibiotic and antipsychotic drugs increases the risk of sudden cardiac arrest (SCA) among people with type 2 diabetes who do not have a history of cardiovascular disease (CVD), shows the first such analysis of real-world, primary care data.

Roughly 2% of prescriptions to older patients appear to be inappropriate — but the figure does not appear to differ between physicians and nurse practitioners, according to a study published last month in Annals of Internal Medicine.

The American Heart Association (AHA) has unveiled a new risk calculator for cardiovascular disease (CVD) designed to capture more helpful, accurate evaluations of a patient’s risks than ever before. The announcement comes just one day before AHA’s annual Scientific Sessions meeting, AHA 23, kicks off in Philadelphia.

The American Heart Association has defined a new medical condition that reflects a strong link between obesity, diabetes, heart and kidney disease. The goal is to recognize the condition known as cardiovascular-kidney-metabolic syndrome or CKM. Goal is to achieve an earlier diagnosis and treatment for persons at risk of dying…

Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic methods to evaluate and classify evidence, provide a foundation for the delivery of quality cardiovascular care.

With recent data demonstrating that lecanemab treatment can slow cognitive and functional decline in early symptomatic Alzheimer disease (AD), it is widely anticipated that this drug and potentially other monoclonal antibody infusions targeting amyloid-β protein will imminently be realistic options for some patients with AD.

The 2023 edition of our list features many first-time topics, and emphasis is on potential risks that could have the biggest impact on patients. The number one topic on this year’s lists has been steadily growing and was exacerbated by the COVID-19 pandemic: the pediatric mental health crisis.

People at high risk for nonalcoholic fatty liver disease (NAFLD), such as those with type 2 diabetes or medically complicated obesity, should be screened for advanced fibrosis, says new guidance from the American Association for the Study of Liver Diseases.